342641-94-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure may offer novel biological activities and therapeutic effects, although further research is needed to validate its efficacy and safety.
Used in Chemical Research:
N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide is used as a research tool in the field of organic chemistry, particularly in the study of indolinones, pyrroles, and amides. It can provide insights into the synthesis, properties, and potential applications of related compounds, contributing to the advancement of chemical knowledge and technology.

InChI:InChI=1/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)

Upstream product

• 56341-41-4 5-fluoroindol-2(3H)-one 
• 452105-33-8 5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 100-36-7 N,N-diethylethylenediamine 
• 253870-02-9 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 590424-05-8 N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide 
• 356068-86-5 N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide 

Downstream Products

• 499220-14-3 sunitinib malate 

Relevant academic research and scientific papers

Malic acid lin's preparation method

The present invention relates to a sunitinib malate preparation method, wherein particularly 2,4-dimethyl-5-aldehyde-1H-pyrrole-3-carboxylic acid is adopted as a starting raw material, carboxyl activation with carbonyl diimidazole is performed, the obtained material and N, N-diethylethylenediamine are subjected to condensation under catalysis of 1-hydroxybenzotriazole to obtain an intermediate 1, the intermediate 1 and 5-fluoro-2-oxindole react to obtain sunitinib, and the sunitinib and malic acid are directly subjected to salifying without separation so as to obtain the target product. The method of the present invention has characteristics of easy operation, high yield and high product purity, and is suitable for industrial production.

Method for preparing sunitinib

The invention relates to a method for preparing sunitinib. According to the method, the sunitinib is prepared by adopting a one-pot method. The method comprises the steps of reacting a starting material 5-fluoroindole-2-ketone with 4-dimethyl-5-aldehyde-1H-pyrrole-3-carboxylic acid to generate an intermediate 5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-subunit) methyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid; and directly reacting the generated intermediate with N,N-diethylethylenediamine without separating the intermediate to form the sunitinib.

Method for recovering and utilizing byproduct of chlorination of phosphorus pentachloride

The invention relates to a technology for comprehensively utilizing the byproduct of chlorination of phosphorus pentachloride, and mainly relates to a post treatment, which scientifically utilizes the excess phosphorus pentachloride reagent. The byproduct is converted into an organic synthesis reagent with a wide application range. The wastes are converted into a valuable resource. The discharge of waste water, waste gas, and waste solid is reduced. The obtained reagent is an excellent active reagent, which is widely used in the chemical industry, pharmacy industry, and material industry. The production cost is reduced, and the environment is protected.

PROCESS FOR THE PREPARATION OF N-[2-DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE

The present invention relates to processes for the preparation of N-[2-(Diethylamino) ethyl]-5-[ (5-fluoro-1, 2 -dihydro-2-oxo-3H-indol-3-ylidene) methyl] -2, 4-dimethyl-I H-pyrrole- 3 -carboxamide of formula (VI).

NOVEL SALTS OF SUNITINIB

The present invention relates to novel pharmaceutically acceptable salts of sunitinib, to processes for their preparation and to pharmaceutical compositions containing them.